BiPER Therapeutics, a biotechnology company focused on developing innovative cancer therapies, has announced a bridge financing of €800,000 to advance its lead drug candidate, BPR001-615, into clinical trials. This first-in-class BiP inhibitor is designed to target gastrointestinal cancers, addressing a critical unmet need in patients overexpressing BiP.
The funding comprises €448,000 in WiSEED convertible bonds, a €200,000 innovation seed loan from Bpifrance, and €100,000 in a reimbursable advance. This financial boost will enable BiPER Therapeutics to finalize regulatory toxicology studies and prepare for Clinical Trial Application (CTA) in Europe and Investigational New Drug (IND) application in the US, planned for Q3 2025.
Targeting BiP in Gastrointestinal Cancers
BPR001-615 is a selective inhibitor of BiP (Binding Immunoglobulin Protein), a key protein involved in cancer cell survival and resistance. Overexpression of BiP is observed in more than 50% of patients with gastrointestinal cancers. The drug candidate has demonstrated efficacy in preclinical studies, both as a single agent and in combination with chemotherapies and immunotherapies. The mechanism of action involves inducing Endoplasmic Reticulum (ER) stress, leading to tumor cell death.
Mehdi Chelbi, co-founder and CEO of BiPER Therapeutics, stated, "We’re extremely pleased with this bridge financing. It gives us the means to progress the final regulatory toxicology studies and to apply for clinical trial authorization and IND for BPR001-615."
Clinical Trial Plans and Market Opportunity
BiPER Therapeutics plans to initiate a Phase 1/2a clinical trial to assess the tolerability of BPR001-615 in patients with gastrointestinal cancers. Following this, the company intends to launch a Phase 2b proof-of-concept efficacy trial specifically in BiP-positive gastric cancers. Gastric cancer represents a significant market, with an estimated one million cases worldwide and an annual projected increase of 2%. Despite advancements in treatment, including immunotherapies, a substantial unmet medical need remains.
The company is currently seeking €30 million in Series A funding to support the clinical trial phases and potentially provide treatment for patients with limited options. BiPER Therapeutics will be attending the 2025 JP Morgan Healthcare Conference to present its progress and meet with potential investors.
Precision Medicine Approach
BiPER Therapeutics is adopting a precision medicine approach by identifying patients who are likely to respond to BPR001-615 through a blood test that measures BiP levels. This strategy aims to improve treatment outcomes and personalize cancer therapy.
